Needham Reiterates Buy on NextCure, Maintains $6 Price Target
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Gil Blum has reiterated a 'Buy' rating on NextCure (NASDAQ:NXTC) and maintained a price target of $6.
August 04, 2023 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst has reiterated a 'Buy' rating on NextCure, maintaining a price target of $6.
The reiteration of a 'Buy' rating by a Needham analyst indicates a positive outlook for NextCure. The maintained price target of $6 suggests that the analyst believes the stock is undervalued at current prices, which could lead to upward pressure on the stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100